Target Price | $163.63 |
Price | $122.21 |
Potential |
33.89%
register free of charge
|
Number of Estimates | 24 |
24 Analysts have issued a price target Neurocrine Biosciences, Inc. 2025 .
The average Neurocrine Biosciences, Inc. target price is $163.63.
This is
33.89%
register free of charge
$192.00
57.11%
register free of charge
$121.00
0.99%
register free of charge
|
|
A rating was issued by 29 analysts: 25 Analysts recommend Neurocrine Biosciences, Inc. to buy, 4 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Neurocrine Biosciences, Inc. stock has an average upside potential 2025 of
33.89%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Revenue Billion $ | 1.89 | 2.35 |
26.76% | 24.42% | |
EBITDA Margin | 22.05% | 30.64% |
23.26% | 38.96% | |
Net Margin | 13.25% | 19.11% |
24.91% | 44.27% |
25 Analysts have issued a sales forecast Neurocrine Biosciences, Inc. 2024 . The average Neurocrine Biosciences, Inc. sales estimate is
This results in the following potential growth metrics:
8 Analysts have issued an Neurocrine Biosciences, Inc. EBITDA forecast 2024. The average Neurocrine Biosciences, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
23 Neurocrine Biosciences, Inc. Analysts have issued a net profit forecast 2024. The average Neurocrine Biosciences, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | 2.47 | 4.43 |
58.33% | 79.35% | |
P/E | 27.57 | |
EV/Sales | 4.87 |
23 Analysts have issued a Neurocrine Biosciences, Inc. forecast for earnings per share. The average Neurocrine Biosciences, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Neurocrine Biosciences, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Neurocrine Biosciences, Inc....
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.